Clinical trial
A Randomized, Double-blind, Parallel-group, Multi-center Phase 3 Comparative Study Investigating Efficacy and Safety of LA-EP2006 and Neulasta® in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy
NCT01735175 is registered in ClinicalTrials.gov with Sandoz as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Parallel-group, Multi-center Phase 3 Comparative Study Investigating Efficacy and Safety of LA-EP2006 and Neulasta® in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy
- Lead sponsor
- Sandoz
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 30, 2012
- Completion date
- February 28, 2014
- Enrollment
- 316 (actual)
- Sites
- 41
Conditions
As the registry lists them; a condition with its own page is linked.
breast neoplasms, chemotherapeutic toxicity, chemotherapy-induced neutropenia, neutropenic complications